Literature DB >> 11007719

Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia.

J H Callicott1, A Bertolino, M F Egan, V S Mattay, F J Langheim, D R Weinberger.   

Abstract

OBJECTIVE: Certain cognitive, behavioral, and emotional deficits (so-called negative symptoms) in patients with schizophrenia have often been attributed to prefrontal cortical pathology, but direct evidence for a relationship between prefrontal neuronal pathology and negative symptoms has been lacking. The authors hypothesized that an in vivo measure of prefrontal neuronal pathology (N:-acetylaspartate [NAA] levels) in patients with schizophrenia would predict negative symptoms.
METHOD: Proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and rating scales for negative and positive symptoms were used to study 36 patients with schizophrenia. Magnetic resonance spectra were analyzed as metabolite ratios, and parametric correlations were performed.
RESULTS: A regionally selective negative correlation was found between prefrontal NAA-creatine ratio and negative symptom ratings in this group of patients with schizophrenia.
CONCLUSIONS: Lower prefrontal NAA-and by inference greater neuronal pathology-predicted more severe negative symptoms in patients with schizophrenia. These data demonstrate a relationship between an intraneuronal measure of dorsolateral prefrontal cortex integrity and negative symptoms in vivo and represent further evidence for the involvement of the dorsolateral prefrontal cortex in negative symptoms associated with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007719     DOI: 10.1176/appi.ajp.157.10.1646

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

2.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

Review 3.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

Review 4.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

5.  Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

Authors:  Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2010-06-08       Impact factor: 13.382

6.  Postmortem degradation of N-acetyl aspartate and N-acetyl aspartylglutamate: an HPLC analysis of different rat CNS regions.

Authors:  J Battistuta; C Bjartmar; B D Trapp
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

Review 7.  [Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations].

Authors:  T Wobrock; H Scherk; P Falkai
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

Review 8.  A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications.

Authors:  George E Jaskiw; Anand P Popli
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

9.  Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia.

Authors:  Meredith A Reid; Nina V Kraguljac; Kathy B Avsar; David M White; Jan A den Hollander; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2013-05-21       Impact factor: 4.939

Review 10.  T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Authors:  Bethany K Bracken; Elizabeth D Rouse; Perry F Renshaw; David P Olson
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.